382 related articles for article (PubMed ID: 27957769)
21. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.
Liu X; Sejbal J; Kotovych G; Koganty RR; Reddish MA; Jackson L; Gandhi SS; Mendonca AJ; Longenecker BM
Glycoconj J; 1995 Oct; 12(5):607-17. PubMed ID: 8595249
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
[TBL] [Abstract][Full Text] [Related]
23. MUC1 glycopeptide epitopes predicted by computational glycomics.
Song W; Delyria ES; Chen J; Huang W; Lee JS; Mittendorf EA; Ibrahim N; Radvanyi LG; Li Y; Lu H; Xu H; Shi Y; Wang LX; Ross JA; Rodrigues SP; Almeida IC; Yang X; Qu J; Schocker NS; Michael K; Zhou D
Int J Oncol; 2012 Dec; 41(6):1977-84. PubMed ID: 23023583
[TBL] [Abstract][Full Text] [Related]
24. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library.
Ohyabu N; Hinou H; Matsushita T; Izumi R; Shimizu H; Kawamoto K; Numata Y; Togame H; Takemoto H; Kondo H; Nishimura S
J Am Chem Soc; 2009 Dec; 131(47):17102-9. PubMed ID: 19899793
[TBL] [Abstract][Full Text] [Related]
25. Synthetic vaccines from tumor-associated glycopeptide antigens.
Westerlind U; Kunz H
Chimia (Aarau); 2011; 65(1-2):30-4. PubMed ID: 21469441
[TBL] [Abstract][Full Text] [Related]
26. Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.
Yin Z; Wu X; Kaczanowska K; Sungsuwan S; Comellas Aragones M; Pett C; Yu J; Baniel C; Westerlind U; Finn MG; Huang X
ACS Chem Biol; 2018 Jun; 13(6):1668-1676. PubMed ID: 29782143
[TBL] [Abstract][Full Text] [Related]
27. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.
Cai H; Sun ZY; Chen MS; Zhao YF; Kunz H; Li YM
Angew Chem Int Ed Engl; 2014 Feb; 53(6):1699-703. PubMed ID: 24449389
[TBL] [Abstract][Full Text] [Related]
28. Molecular basis of antibody binding to mucin glycopeptides in lung cancer.
Qu J; Yu H; Li F; Zhang C; Trad A; Brooks C; Zhang B; Gong T; Guo Z; Li Y; Ragupathi G; Lou Y; Hwu P; Huang W; Zhou D
Int J Oncol; 2016 Feb; 48(2):587-94. PubMed ID: 26692014
[TBL] [Abstract][Full Text] [Related]
29. Covalent bond or noncovalent bond: a supramolecular strategy for the construction of chemically synthesized vaccines.
Gao Y; Sun ZY; Huang ZH; Chen PG; Chen YX; Zhao YF; Li YM
Chemistry; 2014 Oct; 20(42):13541-6. PubMed ID: 25155367
[TBL] [Abstract][Full Text] [Related]
30. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.
Ryan SO; Vlad AM; Islam K; Gariépy J; Finn OJ
Biol Chem; 2009 Jul; 390(7):611-8. PubMed ID: 19426130
[TBL] [Abstract][Full Text] [Related]
31. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
[TBL] [Abstract][Full Text] [Related]
32. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.
Beckwith DM; Cudic M
Semin Immunol; 2020 Feb; 47():101389. PubMed ID: 31926647
[TBL] [Abstract][Full Text] [Related]
33. Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue.
Hoffmann-Röder A; Kaiser A; Wagner S; Gaidzik N; Kowalczyk D; Westerlind U; Gerlitzki B; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2010 Nov; 49(45):8498-503. PubMed ID: 20878823
[No Abstract] [Full Text] [Related]
34. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response.
Westerlind U; Hobel A; Gaidzik N; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2008; 47(39):7551-6. PubMed ID: 18704911
[No Abstract] [Full Text] [Related]
35. Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles.
Wu X; McKay C; Pett C; Yu J; Schorlemer M; Ramadan S; Lang S; Behren S; Westerlind U; Finn MG; Huang X
ACS Chem Biol; 2019 Oct; 14(10):2176-2184. PubMed ID: 31498587
[TBL] [Abstract][Full Text] [Related]
36. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine.
Hanisch FG; Ninkovic T
Curr Protein Pept Sci; 2006 Aug; 7(4):307-15. PubMed ID: 16918445
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
Sarkar S; Salyer AC; Wall KA; Sucheck SJ
Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines.
Xiao A; Zheng XJ; Song C; Gui Y; Huo CX; Ye XS
Org Biomol Chem; 2016 Jul; 14(30):7226-37. PubMed ID: 27380866
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of a glycopeptide vaccine conjugate for induction of antibodies recognizing O-mannosyl glycopeptides.
Yu J; Westerlind U
Chembiochem; 2014 May; 15(7):939-45. PubMed ID: 24753400
[TBL] [Abstract][Full Text] [Related]
40. Synthetic glycopeptides for the development of cancer vaccines.
Liakatos A; Kunz H
Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
